Measuring COVID-19 Humoral Immune Response with Ultrasensitive, Cell-Free, PCR-Based Neutralizing Antibody Assays

Build a Complete Picture of Immune Response

As we look to manage the next phase of the pandemic, it is important to understand the body’s immune response to SARS-CoV-2 vaccines. Most antibody testing detects all antibodies in a sample, although only neutralizing antibodies (NAbs) inhibit the virus from attaching to cells. Building a complete picture of immune response, including the role of NAbs, is critical as we face the continued emergence of new variants.

However, cell-based assays, the current gold standard for SARS-CoV-2 NAb testing, require additional safety measures for managing live viruses. These involve long, complicated workflows with poor lab-to-lab consistency. While some Elisa-based solutions are available, they lack sensitivity and don’t produce a quantitative measurement.

In this webinar we will learn about a new approach to this problem using a new proprietary method that leverages qPCR to produce quantified Nab titers.

Learning Objectives

This webinar will help you:

• Explain the importance of NAb testing and the need for standard testing methods
• Review current COVID-19 antibody testing options
• Describe a new technology being used for SARS-CoV-2 NAb testing
• Examine NAb data for vaccination and emerging variants

For research use only. Not for diagnostic procedures.

Fisher Healthcare is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.™ Program. One P.A.C.E.™ credit-hour will be provided for this complimentary basic level program.